RCUS Q3 2021 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-85.3% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$78M-825.9% margin

Net Income

-$78M-824.2% margin

EPS (Diluted)

$-1.11

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$62M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$839M

Total Liabilities

$297M

Stockholders' Equity

$543M

Cash & Equivalents

$179M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$65M	-85.3%
Gross Profit	$9M	$65M	-85.3%
Operating Income	-$78M	$2M	-5134.5%
Net Income	-$78M	$2M	-4379.6%

Revenue Segments

Collaboration

$8M100%